Delivery Order SPE2DR25D1053-SPE2DR26FT765
Award Date 11/10/25
Potential Completion Date 12/3/25
Potential Value $76K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a contract ceiling value of $43,178.96 under firm fixed price terms. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 16, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical product used in the treatment of...
- The Defense Logistics Agency awarded a $53,535.55 delivery order to AmerisourceBergen Drug Corp for 4,569,471,727 units of Ocrevus 300 mg/10 mL vials on September 16, 2025, with an ultimate completion date of October 7, 2025. This competitively awarded, firm fixed price contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Ocrevus is a monoclonal antibody treatment used primarily for multiple sclerosis, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials, with a ceiling value of $24,038.58 and a firm fixed price structure. This delivery order is a non-set-aside competitive award with a completion deadline of December 1, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Ocrevus is a monoclonal antibody used primarily to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $72,115.74. This is a firm fixed-price delivery order with an ultimate completion date of September 15, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp will perform this work at its corporate office location in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical product...
- The Defense Logistics Agency awarded a $63,767.62 delivery order to AmerisourceBergen Drug Corp for Ocrevus 300 mg/10 ml vials on September 8, 2025, with completion targeted for September 29, 2025. This is a firm fixed-price delivery order issued under a non-competitive set-aside arrangement. Ocrevus is a monoclonal antibody used primarily for treating multiple sclerosis, reflecting the pharmaceutical distributor's role in supplying specialized medications to support military and veteran...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 25, 2025, with a contract ceiling value of $24,038.58 and an ultimate completion date of September 16, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under DLA's procurement processes. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ocrevus 300 mg/10 ml vials on September 26, 2025, with an ultimate completion date of October 20, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ocrevus is a disease-modifying therapy used to treat multiple sclerosis, reflecting the...
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $69,910.72 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of October 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ocrevus is a biologic medication used primarily for the treatment...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $120,192.80 and firm fixed pricing. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This is an unrestricted, competitively awarded delivery order with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet...